Lindsay Androski
President, CEO & ChairmanMs. Lindsay Androski, JD, MBA, is Interim President, CEO & Director of Arbutus Biopharma Corporation from February 25, 2025 and also serves as its Chairman since February 2025. She served as an Independent Director at Eloxx Pharmaceuticals, Inc. since July 2022 until August 6, 2025. She is founder, President and CEO of Roivant Social Ventures. Ms. Androski is an MIT-trained biologist with experience in the areas of biotechnology, law and academia. She has served in a variety of roles at Roivant. She is special counsel at Genevant with responsibilities including LNP litigation. A noted expert in the creation, launch and scaling of biotech companies, Ms. Androski joined the founding team at Roivant Sciences to build and lead group responsible for the in-license or acquisition of more than 30 pharmaceutical drug candidates, where she was also instrumental in the launch of 16 biotech companies and participated in three IPOs and several private financings. To date, these efforts have led to five approved drugs available to patients: Orgovyx (prostate cancer), Myfembree (heavy menstrual bleeding / uterine fibroids), Gemtesa (overactive bladder), Rethymic (pediatric congenital athymia) and VTAMA (plaque psoriasis). Prior to joining Roivant Sciences, Ms. Androski spent many years as a trial lawyer, including few years as an Assistant U.S. Attorney in the newly-launched Cybercrime unit of the Eastern District of Virginia, where she led investigations and prosecutions of high-profile cybercrime and national security cases. Ms. Androski holds two BS degrees from the Massachusetts Institute of Technology, JD and MBA degrees from The University of Chicago, is a registered Patent Lawyer and a CFA charterholder (under her former name of Lindsay Androski Kelly). Ms. Androski also serves as a Trustee of the Massachusetts Institute of Technology and sits on the Visiting Committees for the Department of Biology, the Department of Humanities and Sponsored Research.
Positions
- Company NameArbutus Biopharma CorporationStock CodeABUSPositionPresident, CEO & Chairman
